Quick Answer
Arcturus Therapeutics Holdings Inc. reported Earnings Per Share Diluted of $2.40 (loss) per share for the year ending 2025.
- Arcturus Therapeutics Holdings Inc. showed an increase of +20.0% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Arcturus Therapeutics Holdings Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $2.07 (loss) per share | Q3 2021: $2.05 (loss) per share | Q1 2022: $1.94 (loss) per share | Q2 2022: $0.82 (loss) per share | Q3 2022: $1.33 (loss) per share | Q1 2023: $1.87 per share | Q2 2023: $1.98 (loss) per share | Q3 2023: $0.61 (loss) per share | Q1 2024: $1.00 (loss) per share | Q2 2024: $0.64 (loss) per share | Q3 2024: $0.26 (loss) per share | Q1 2025: $0.52 (loss) per share | Q2 2025: $0.34 (loss) per share | Q3 2025: $0.49 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Arcturus Therapeutics Holdings Inc.'s Earnings Per Share Diluted has grown by 69.0%.
- Historical annual values: Fiscal year 2025: $2.40 (loss) per share | Fiscal year 2024: $3.00 (loss) per share | Fiscal year 2023: $1.12 (loss) per share | Fiscal year 2022: $0.35 per share | Fiscal year 2021: $7.74 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: